Precigen director Nancy H. Agee buys $24,661 of PGEN stock By Investing.com

Precigen director Nancy H. Agee recently increased her stake in the biotechnology company, purchasing shares worth $24,661.

According to a Form 4 filing, Ms. Agee acquired 3,411 shares of Precigen () common stock on August 21, 2026. The shares were purchased at a price of $7.23 per share.

Following this transaction, Ms. Agee directly holds 309,187 shares of Precigen common stock.The insider purchase comes as Precigen shares trade near their 52-week high of $7.55, having delivered a 71% return over the past year. According to InvestingPro analysis, the stock appears fairly valued at current levels, with analysts setting price targets between $11 and $18. For deeper insights into Precigen’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Precigen reported a significant second-quarter performance, surpassing expectations for both earnings and revenue. The company achieved earnings of $0.05 per share, a notable improvement over the anticipated $0.01 loss. Revenue reached $54.98 million, nearly doubling the analyst forecast of $27.83 million. This strong financial performance was largely driven by the robust demand for PAPZIMEOS, Precigen’s approved therapy for adult recurrent respiratory papillomatosis. The company reported a net income of $20.1 million for the quarter. These developments highlight Precigen’s strong market position and successful product launch. Investors and analysts are closely watching the company’s progress, given its recent financial achievements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.